Introduction
The vasopressin analogue desmopressin (dDAVP, 1) is a potent V2 receptor agonist that also activates the related V1b receptor [1] . dDAVP is approved in many countries for the treatment of diabetes insipidus, primary nocturnal enuresis, nocturia, and coagulation disorders including hemophilia A and von Willebrand's disease.
In search of novel, potent, selective and pharmacologically useful peptidic V2R agonists, we synthesized a series of C-terminally truncated [Val4]dDAVP (2) [2] analogs modified in positions 2, 3, 7 and/or at the disulfide bridge. The peptides were evaluated for in vitro potency at the humanV2 receptor (hV2R) and selectivity versus related receptors (hV1aR, hV1bR, hOTR). Here we present comprehensive in vitro data for the new compounds and describe synthetic methods used to prepare the analogues.
Results and Discussion
Analogues 3-24 (Table 1) were synthesized by a combination of solid and solution phase chemistry. The linear precursors of compounds 3-13, 22 were assembled on H-Aaa-O-2-ClTrt resins by standard Fmoc chemistry using DIC/HOBt mediated couplings. The carba thioether modifications of the disulfide bridge (X or Y = CH2, Figure 1 ) were introduced to the peptide sequence by coupling FmocCys((CH2)3-COOtBu)-OH or Fmoc-Hcy((CH2)2-COOtBu)-OH [3] . Fully protected peptide C-terminal acids were cleaved with 30% HFIP/DCM. For compounds 3-10 the carboxylic group was reduced to the hydroxymethyl group using mixed anhydride method [4] . For compounds 11-13 the C-terminal acids were coupled with agmatine and for analogue 22 the linear fragment was coupled with H-DArg(Pbf)-NEt2. The protecting groups were removed with the TFA/TIS/H2O 95/2.5/2.5 cocktail and the linear peptides were cyclized in DMF using HBTU/DIPEA method. The linear precursor of peptide 14 was assembled on 1,4-diaminobutane-2-ClTrt resin. After cleavage from the resin the C-terminal amino function was temporarily protected with the TFA resistant Z(2-Cl) group. The peptide was deprotected and cyclized as described above. The Z(2-Cl) group was removed with TMSBr/thioanisole/TFA (1/1/6) [5] . The linear precursors of compounds 15-21, 23 and 24 were synthesized on BAL resin which was reductively alkylated with an appropriate primary amine prior to the peptide assembly. The peptides were cleaved with concomitant side chain protecting group removal using the TFA cocktail and cyclized as described above. All peptides were purified by preparative HPLC and lyophilized.
The pharmacological profile of 1 was determined in in vitro assays and was consistent with the literature data [1] . 1 was particularly selective vs. the V1aR (>1000-fold) presumably due to the desamino modification [6] . The Val 4 analogue of 1 ([Val 4 ]dDAVP, 2) has been reported to be more potent and selective than 1 in rat in vivo models [7] . This profile is consistent with our in vitro studies at the human receptors (Table 1) . Manning, et al. investigated the impact of the C-terminal Gly residue removal on the antidiuretic activity of 1, 2 and related peptides in rats [7] . The corresponding desglycine analogues retained 10 -50% initial antidiuretic activity, suggesting C-terminal truncation could be a good strategy to design novel V2R agonists. First, the C-terminal group R 1 (-C(=O)-Gly-NH2) in compound 2 was replaced with the hydroxymethyl function and the analogues were also modified in position 2, 3 and at the disulfide bridge (compounds 3-10). The disulfide bridge modifications (X, Y) as well as the configuration of the *C chiral carbon had very little impact on potency and selectivity profiles. Compounds in this series were potent hV2R agonists with 9 and 10 (Ar 1 = 4-alkylphenyl) being about 2-fold less potent at the V2R than 1. Analogues 3-10 displayed improved selectivity versus both the hV1bR (all partial agonists) and hOTR except for the Tyr 2 compounds 3 and 4 (Ar 1 = 4-hydroxyphenyl) that were less selective vs. hOTR than 2. Peptide 8 where Ar 2 = 4-fluorophenyl was less potent as an hV2R agonist than its 2-thienyl counterpart 5.
Next, we investigated if the substituent R 1 is actually required to preserve high agonistic potency at the hV2R (compounds 11-14) . Compound 12 (R 1 = H, Ar 1 = 4-chlorophenyl, Ar 2 = 2-thienyl) was found to be very potent and considerably more selective than 2. The Thz 7 modification (Z = S) was found to be neutral in this series as analogues 12 and 13 had very similar pharmacological profiles. In addition we demonstrated that the guanidino function (R 2 = -C(=NH)NH2) does not appear to be essential to preserve hV2R agonism (compound 14, R 2 = H). Lastly, we explored if the C-terminal glycine amide could be replaced with alkyl groups (R substituents were well tolerated and rather shallow SAR was observed. The isopropyl compound 19 (R 3 = iPr, R 4 = H) was the least potent V2R agonist in this subset. The Thz 7 modification was advantageous as exemplified by a 3-fold increase in potency for peptide 24 (Z = S) vs. 16 (Z = CH2). Double alkylation, e.g. compound 22 (R 3 = R 4 = Et), was also well tolerated while maintaining excellent selectivity vs. the related receptors.
In conclusion, a series of novel C-terminally truncated dDAVP analogues with improved in vitro pharmacological profile has been identified. The novel compounds retain the potent V2 receptor agonism activity of dDAVP, 1. Compounds 5-13 and 15-24 display substantially improved selectivities vs. hV1aR, hV1bR and hOTR as compared to 1 and 2.
